Claims
- 1. An isolated Slit-N polypeptide.
- 2. A Slit-N polypeptide according to claim 1, wherein the Slit-N polypeptide is selected from an hSlit-1-N, an hSlit-2-N and an hSlit-3-N polypeptide
- 3. A Slit-N polypeptide according to claim 1, contained in a pharmaceutical composition.
- 4. A Slit-N polypeptide according to claim 1, made by expressing a Slit protein in a cell, whereby the Slit protein is proteolytically processed to form the Slit-N polypeptide.
- 5. A recombinant polynucleotide comprising a coding region encoding a Slit-N polypeptide according to claim 1, said coding region flanked by fewer than 500 nucleotides of native flanking sequence.
- 6. A pharmaceutical composition comprising a therapeutically effective amount of a Slit-N polypeptide according to claim 1, and a pharmaceutically acceptable excipient.
- 7. A pharmaceutical composition comprising a therapeutically effective amount of a Slit-N polypeptide according to claim 1, and a pharmaceutically acceptable excipient, wherein the Slit-N polypeptide is selected from an hSlit-1-N, an hSlit-2-N and an hSlit-3-N polypeptide
- 8. A pharmaceutical composition comprising a therapeutically effective amount of a Slit-N polypeptide according to claim 1, and a pharmaceutically acceptable excipient, further comprising a therapeutically effective amount of a neuroactive agent other than the Slit-N polypeptide.
- 9. A pharmaceutical composition comprising a therapeutically effective amount of a Slit-N polypeptide according to claim 1, and a pharmaceutically acceptable excipient, further comprising a therapeutically effective amount of a neuroactive agent other than the Slit-N polypeptide, wherein the agent is NGF.
- 10. A method of promoting axon branching or sprouting, comprising contacting a neuron with a composition comprising an effective amount of a Slit-N polypeptide according to claim 1.
- 11. A method of treating a neuropathy comprising administering a composition comprising a therapeutically effective amount of a Slit-N polypeptide according to claim 1.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. application, Ser. No. (not yet assigned), having the same title and inventors, filed Mar. 18, 1999. Slit compositions are subject to claims in copending U.S. application, Ser. No. 09/191,647, having the same assignee:
Provisional Applications (1)
|
Number |
Date |
Country |
|
60125591 |
Mar 1999 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09273098 |
Mar 1999 |
US |
Child |
10721407 |
Nov 2003 |
US |